2 heads better than 1 in new antibiotic method

Dec 03, 2009

An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibacterial drugs.

"A completely new way to beat is an exciting find at a time when resistance to existing antibiotics is growing," said Professor Tony Maxwell from the John Innes Centre, lead author on the research to be published in Science. JIC is an institute of the BBSRC.

The antibiotic molecule slots into pockets in the surface of a , DNA gyrase, and inhibits its activity. Gyrase is essential for bacteria to survive and grow. However, it is not present in humans so is an ideal, and already established, target for antibiotics.

"If you can knock out this enzyme, you have a potential new drug," says Prof Maxwell.

The molecule has two heads that dock into separate pockets in DNA gyrase, and together they are 100 times more powerful than when working individually. Neither pocket has previously been exploited by antibacterial drugs that target this enzyme. Although bacteria could develop resistance to this mode of action, it might be occur less readily than with other .

"The fact that there are two pockets means that it might require simultaneous mutations in both pockets for the bacteria to acquire full resistance to the drug, which is much less likely," explains Professor Maxwell.

"You could say that this is a case of two heads being better than one."

The antibiotic molecule, simocyclinone D8 (SD8), is a currently unexploited natural product made by soil bacteria. SD8 itself does not easily penetrate bacterial cells, but it raises the possibility of finding other molecules that fit into the binding pockets, or designing molecules that work by this mechanism but that penetrate cells more easily.

The current method of discovery is to screen protein targets or bacteria against vast libraries of compounds. Any hits are investigated in more detail.

The research reported in Science is a big advance as the scientists already know in detail how the molecule works. It can now be modified, or new compounds developed, to design new drugs.

Source: Norwich BioScience Institutes

Explore further: Biomedical engineer looks at new applications for novel lupus drug

add to favorites email to friend print save as pdf

Related Stories

Energy-saving bacteria resist antibiotics

Sep 03, 2008

Bacteria save energy by producing proteins that moonlight, having different roles at different times, which may also protect the microbes from being killed. The moonlighting activity of one enzyme from the tuberculosis bacterium ...

The structure of resistance

Feb 22, 2008

A team of scientists from the University Paris Descartes has solved the structure of two proteins that allow bacteria to gain resistance to multiple types of antibiotics, according to a report in EMBO reports this month. ...

Decoy makes sitting duck of superbugs

Dec 04, 2007

Scientists from the John Innes Centre have proven that by taking a short stretch of DNA from a bacterium and delivering it with an existing antibiotic they can switch off antibiotic resistance.

Recommended for you

Immune response may cause harm in brain injuries, disorders

55 minutes ago

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, ...

One route to malaria drug resistance found

4 hours ago

Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug. The discovery, at Washington University School of Medicine in St. Louis, also is relevant for other infectious ...

Protein therapy successful in treating injured lung cells

5 hours ago

Cardiovascular researchers at The Ohio State University Wexner Medical Center have successfully used a protein known as MG53 to treat acute and chronic lung cell injury. Additionally, application of this protein proved to ...

User comments : 0